ArticleFrontiers in immunology2026
Diagnostic performance of serum 14-3-3η protein versus conventional serological markers in early rheumatoid arthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Conventional biomarkers for rheumatoid arthritis (RA) only have a ~70% sensitivity, making early diagnosis difficult. With its high concentration in synovial fluid, the 14-3-3η protein is a promising new biomarker for the early identification of RA in Chinese people. Methods: In this case-control study, 90 disease controls, 110 healthy controls, 72 established RA patients, and 56 early RA patients were enrolled. The 14-3-3η protein's diagnostic performance was evaluated utilizing ROC curve analysis in comparison to anti-CCP antibodies, RF, CRP, IgM, and ESR. To control for confounding variables, multivariable logistic regression models that were adjusted for sex and age were used. Results: 14-3-3η showed exceptional diagnostic performance, with AUC ≥0.85 for both early and developed RA. In early RA, anti-CCP demonstrated better specificity (96.4%) and a positive likelihood ratio (21.2%), while 14-3-3η had the highest sensitivity (88.1%) and the lowest negative likelihood ratio (0.14). There were no significant associations between 14-3-3η and traditional markers (P>0.05) according to Spearman correlation analysis. Conclusions: 14-3-3η protein serves as an independent and highly sensitive biomarker for early RA diagnosis, particularly valuable for ruling out disease. These biomarkers, combined with the high specificity of anti-CCP, provide supplementary diagnostic benefits for complete early RA assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.